sheep anti lyve 1 antibody Search Results


90
NSJ Bioreagents rabbit
Rabbit, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm32640183-334-3-13?v=NSJ+Bioreagents
Average 90 stars, based on 1 article reviews
rabbit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Rockland Immunochemicals secondary antibodies against cd31
Secondary Antibodies Against Cd31, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm27574793-366-39-52?v=Rockland+Immunochemicals
Average 90 stars, based on 1 article reviews
secondary antibodies against cd31 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

93
R&D Systems sheep anti rat lyve1
Figure 2. Three-dimensional (3-D) visualization of lymphatic vessels in the portal tract of normal mouse and human livers. A, left: reconstructed 3-D image of the portal tract in the normal mouse liver. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,290 μm 1,290 μm 354 μm. Liver tissue was cleared and stained with <t>LYVE1</t> (red, lymphatic vessel), ASMA (white, portal vein), and CK19 (green, bile duct) antibodies. Right: 3-D volume-rendering image of lymphatic vessels and bile ducts using Imaris software with an enlarged image. Scale bars: 100 μm. B: reconstructed 3-D image of the portal tract in normal human liver tissue. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,002 μm 1,168 μm 228 μm. Liver tissue was cleared and stained with PDPN (red, lymphatic vessel) and ASMA (white, portal vein) antibodies. Scale bar: 100 μm. C, left: recon- structed 3-D image of the portal tract in normal human liver tissue. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,193 μm 1,193 μm 233 μm. Liver tissue was cleared and stained with PDPN (red, lymphatic vessel) and CK19 (green, bile duct) antibodies. Right, top: enlarged reconstructed 3-D image. Right, bottom: 3-D volume-rendering image. Scale bars: 100 μm.
Sheep Anti Rat Lyve1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm37605828-96-47-52?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
sheep anti rat lyve1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

99
R&D Systems goat anti mouse lyve1
β-Catenin is necessary for the development of LVVs, LVs, VVs, and cardiac valves. ( A – J ) The gene encoding β-catenin ( Ctnnb1 ) was deleted from LECs, LVV-ECs, LV-ECs, and VV-ECs using <t>Lyve1-Cre</t> mice . IHC was performed for the indicated markers. Frontal sections from E14.5 ( A – D ) and E16.5 ( G , H ) embryos revealed the LVVs in controls (arrows) but not in their Lyve1-Cre; Ctnnb1 LOF littermates. Arrowheads point to the valve-forming area of mutants. ( G , H ) At E16.5, VVs are seen in control embryos (yellow arrows) but not in mutants. ( E , F ) SEM confirmed the presence of LVV-ECs (magenta) and VV-ECs (green) in E14.5 control embryos and their absence in Lyve1-Cre;Ctnnb1 LOF littermates. ( I , J ) Whole-mount IHC of the mesenteric lymphatic vessels revealed the presence of LVs in E18.5 control (arrows) but not Lyve1-Cre;Ctnnb1 LOF littermates. ( I ) Furthermore, PROX1 is strongly expressed in the LVs but down-regulated elsewhere in the lymphatic vessels of controls. ( J ) In contrast, PROX1 expression is uniformly high in the lymphatic vessels of the mutants. ( K , L ) Prox1 +/ Cre was used to delete Ctnnb1 from the PROX1 + cells of the cardiac semilunar valves. IHC was performed for the indicated markers. E13.5 Prox1 +/ Cre ; Ctnnb1 LOF embryos lacked the PROX1 + FOXC2 + cells of the cardiac valves (arrows). (LS) Lymph sacs; (IJV) internal jugular vein; (SCV) subclavian vein; (SVC) superior vena cava. Bars: A – J , 200 µm; K , L , 100 µm. n = 4 for each experiment.
Goat Anti Mouse Lyve1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pmc04926867-273-26-29?v=R%26D+Systems
Average 99 stars, based on 1 article reviews
goat anti mouse lyve1 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

94
R&D Systems anti mouse lyve1
( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and <t>LYVE1</t> (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.
Anti Mouse Lyve1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pmc07478896-24-2-7?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
anti mouse lyve1 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

94
R&D Systems rat mab against lyve 1 223322 ag
( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and <t>LYVE1</t> (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.
Rat Mab Against Lyve 1 223322 Ag, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm31767783-67-0-19?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
rat mab against lyve 1 223322 ag - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

93
R&D Systems rat anti lyve 1
( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and <t>LYVE1</t> (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.
Rat Anti Lyve 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/10__7554_slash_elife__46206-279-29-31?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
rat anti lyve 1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

90
Novus Biologicals rat anti lyve 1
( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and <t>LYVE1</t> (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.
Rat Anti Lyve 1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pmc04753256-163-86-88?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
rat anti lyve 1 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

94
R&D Systems rat anti lyve1
( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and <t>LYVE1</t> (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.
Rat Anti Lyve1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm31369756-62-10-13?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
rat anti lyve1 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology rat anti lymphatic vessel endothelial hyaluronan receptor 1 lyve 1
( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and <t>LYVE1</t> (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.
Rat Anti Lymphatic Vessel Endothelial Hyaluronan Receptor 1 Lyve 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pmc04639986-483-54-69?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
rat anti lymphatic vessel endothelial hyaluronan receptor 1 lyve 1 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

93
OriGene anti lyve1
( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and <t>LYVE1</t> (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.
Anti Lyve1, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sheep+anti+lyve+1+antibody/pm38200313-598-46-50?v=OriGene
Average 93 stars, based on 1 article reviews
anti lyve1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


Figure 2. Three-dimensional (3-D) visualization of lymphatic vessels in the portal tract of normal mouse and human livers. A, left: reconstructed 3-D image of the portal tract in the normal mouse liver. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,290 μm 1,290 μm 354 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel), ASMA (white, portal vein), and CK19 (green, bile duct) antibodies. Right: 3-D volume-rendering image of lymphatic vessels and bile ducts using Imaris software with an enlarged image. Scale bars: 100 μm. B: reconstructed 3-D image of the portal tract in normal human liver tissue. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,002 μm 1,168 μm 228 μm. Liver tissue was cleared and stained with PDPN (red, lymphatic vessel) and ASMA (white, portal vein) antibodies. Scale bar: 100 μm. C, left: recon- structed 3-D image of the portal tract in normal human liver tissue. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,193 μm 1,193 μm 233 μm. Liver tissue was cleared and stained with PDPN (red, lymphatic vessel) and CK19 (green, bile duct) antibodies. Right, top: enlarged reconstructed 3-D image. Right, bottom: 3-D volume-rendering image. Scale bars: 100 μm.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.

doi: 10.1152/ajpgi.00139.2023

Figure Lengend Snippet: Figure 2. Three-dimensional (3-D) visualization of lymphatic vessels in the portal tract of normal mouse and human livers. A, left: reconstructed 3-D image of the portal tract in the normal mouse liver. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,290 μm 1,290 μm 354 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel), ASMA (white, portal vein), and CK19 (green, bile duct) antibodies. Right: 3-D volume-rendering image of lymphatic vessels and bile ducts using Imaris software with an enlarged image. Scale bars: 100 μm. B: reconstructed 3-D image of the portal tract in normal human liver tissue. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,002 μm 1,168 μm 228 μm. Liver tissue was cleared and stained with PDPN (red, lymphatic vessel) and ASMA (white, portal vein) antibodies. Scale bar: 100 μm. C, left: recon- structed 3-D image of the portal tract in normal human liver tissue. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,193 μm 1,193 μm 233 μm. Liver tissue was cleared and stained with PDPN (red, lymphatic vessel) and CK19 (green, bile duct) antibodies. Right, top: enlarged reconstructed 3-D image. Right, bottom: 3-D volume-rendering image. Scale bars: 100 μm.

Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17), sheep anti-rat LYVE1 (1:100, AF7939, R&D Systems) (18), and rabbit anti-COL-I (1:100, ab292, Abcam) (19) primary antibodies at 4 C overnight, followed by washing with PBS for 5 min for 3 times and incubation with secondary antibodies including donkey anti-goat Alexa 647 (1:300, A32849, Invitrogen), donkey anti-sheep Alexa 647 (1:300, A21448, Invitrogen), and donkey anti-rabbit Alexa 488 at room temperature for 30 min. For immunostaining of PDPN in human liver slides, we amplified fluorescence signal using the avidin-biotin amplification method (SP-2001, Vector Laboratories, Newark, CA).

Techniques: Imaging, Staining, Software

Figure 3. Lymphatic vessels in the capsular area of normal mouse, rat, and human livers. A: comparison of the capsular areas (thickness) among normal human (n ¼ 4), mouse (n ¼ 7), and rat livers (n ¼ 7) stained with Sirius Red. Scale bars: 100 μm. B: two-dimensional (2-D) conventional histology images of the capsular areas (paraffin section, 7-lm thickness) from normal human, mouse, and rat livers stained with PDPN or LYVE1 (red, lymphatic vessel) and Col-I (green, collagenous capsular area), respectively. Yellow arrows indicate lymphatic vessels inside the Col-I positive capsular area. 2-D images were merged with differential interference contrast (DIC) images. Scale bars: 100 μm. C: surface of human liver tissue (top) covered by thin collagenous cap- sule (Glisson’s capsule, yellow arrowhead, bottom) was isolated from normal human liver tissue to visualize capsular lymphatic vessels. D, left: recon- structed 3-D image of lymphatic vessels (PDPN, red) in the capsular area of normal human liver tissue. Imaging condition: z-step size ¼ 0.3 μm, image volume [x] [y] [z] ¼ 1,551 μm 1,551 μm 145 μm. Scale bars: 100 μm. Right: 3-D volume-rendering image. Scale bars: 100 μm.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.

doi: 10.1152/ajpgi.00139.2023

Figure Lengend Snippet: Figure 3. Lymphatic vessels in the capsular area of normal mouse, rat, and human livers. A: comparison of the capsular areas (thickness) among normal human (n ¼ 4), mouse (n ¼ 7), and rat livers (n ¼ 7) stained with Sirius Red. Scale bars: 100 μm. B: two-dimensional (2-D) conventional histology images of the capsular areas (paraffin section, 7-lm thickness) from normal human, mouse, and rat livers stained with PDPN or LYVE1 (red, lymphatic vessel) and Col-I (green, collagenous capsular area), respectively. Yellow arrows indicate lymphatic vessels inside the Col-I positive capsular area. 2-D images were merged with differential interference contrast (DIC) images. Scale bars: 100 μm. C: surface of human liver tissue (top) covered by thin collagenous cap- sule (Glisson’s capsule, yellow arrowhead, bottom) was isolated from normal human liver tissue to visualize capsular lymphatic vessels. D, left: recon- structed 3-D image of lymphatic vessels (PDPN, red) in the capsular area of normal human liver tissue. Imaging condition: z-step size ¼ 0.3 μm, image volume [x] [y] [z] ¼ 1,551 μm 1,551 μm 145 μm. Scale bars: 100 μm. Right: 3-D volume-rendering image. Scale bars: 100 μm.

Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17), sheep anti-rat LYVE1 (1:100, AF7939, R&D Systems) (18), and rabbit anti-COL-I (1:100, ab292, Abcam) (19) primary antibodies at 4 C overnight, followed by washing with PBS for 5 min for 3 times and incubation with secondary antibodies including donkey anti-goat Alexa 647 (1:300, A32849, Invitrogen), donkey anti-sheep Alexa 647 (1:300, A21448, Invitrogen), and donkey anti-rabbit Alexa 488 at room temperature for 30 min. For immunostaining of PDPN in human liver slides, we amplified fluorescence signal using the avidin-biotin amplification method (SP-2001, Vector Laboratories, Newark, CA).

Techniques: Comparison, Staining, Isolation, Imaging

Figure 4. Spatial relationship between lymphatic vessels and bile ducts in biliary cirrhotic livers. A: reconstructed three-dimensional (3-D) image of the portal tract in the liver from a sham-operated mouse (EC-GFP reporter mouse). Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,025 μm 1,161 μm 211 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel: LV) and CK19 (white, bile duct: BD). Scale bar: 100 μm. B: reconstructed 3-D image of the portal tract in the liver from a 4-wk BDL mouse (EC-GFP reporter mouse) with a representative single optical sec- tion in the right. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 862 μm 939 μm 220 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel) and CK19 (white, bile duct). LV, lymphatic vessel; BD, bile duct; PV, portal vein; HA, hepatic artery; PBP: peribili- ary plexus. Scale bars: 100 μm. C: 3-D volume-rendering image of lymphatic vessels and bile ducts in the portal tract with enlarged images (D–F). Scale bar: 100 μm. BDL, bile duct ligation; EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.

doi: 10.1152/ajpgi.00139.2023

Figure Lengend Snippet: Figure 4. Spatial relationship between lymphatic vessels and bile ducts in biliary cirrhotic livers. A: reconstructed three-dimensional (3-D) image of the portal tract in the liver from a sham-operated mouse (EC-GFP reporter mouse). Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 1,025 μm 1,161 μm 211 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel: LV) and CK19 (white, bile duct: BD). Scale bar: 100 μm. B: reconstructed 3-D image of the portal tract in the liver from a 4-wk BDL mouse (EC-GFP reporter mouse) with a representative single optical sec- tion in the right. Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 862 μm 939 μm 220 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel) and CK19 (white, bile duct). LV, lymphatic vessel; BD, bile duct; PV, portal vein; HA, hepatic artery; PBP: peribili- ary plexus. Scale bars: 100 μm. C: 3-D volume-rendering image of lymphatic vessels and bile ducts in the portal tract with enlarged images (D–F). Scale bar: 100 μm. BDL, bile duct ligation; EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.

Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17), sheep anti-rat LYVE1 (1:100, AF7939, R&D Systems) (18), and rabbit anti-COL-I (1:100, ab292, Abcam) (19) primary antibodies at 4 C overnight, followed by washing with PBS for 5 min for 3 times and incubation with secondary antibodies including donkey anti-goat Alexa 647 (1:300, A32849, Invitrogen), donkey anti-sheep Alexa 647 (1:300, A21448, Invitrogen), and donkey anti-rabbit Alexa 488 at room temperature for 30 min. For immunostaining of PDPN in human liver slides, we amplified fluorescence signal using the avidin-biotin amplification method (SP-2001, Vector Laboratories, Newark, CA).

Techniques: Imaging, Staining, Ligation

Figure 5. A workflow for quantification of lymphatic vessel parameters in 3-D volume images. Cleared liver tissue was stained with LYVE1 (red) for lym- phatic vessels (LVs) and reconstructed three-dimensional (3-D) images of the portal tract in the mouse liver (EC-GFP reporter mouse) were created. The “Surface” rendering tool in Imaris software were used to determine a total volume of LYVE1-positive LVs (A–C), whereas the “Filament Tracer” rendering tool was used for quantification of the diameter and branch number of LVs (D–F). A:LYVE1-positive LVs were captured based on fluorescence intensities. B: thresholds were manually adjusted to determine LVs. C:Rendered LYVE1-positive LVs were visually checked to confirm proper vascular connections. LVs with improper connections and/or speckled background structure were removed manually. D: LYVE1-positive LVs were captured based on fluores- cence intensities using automatic filament and path detection in the “Filament Tracer” rendering tool. E: thresholds were manually adjusted to determine LVs. F: LVs with disconnected and speckled background structures were removed manually. All outputs of LV parameters were exported to Excel files for statistical analysis. EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.

doi: 10.1152/ajpgi.00139.2023

Figure Lengend Snippet: Figure 5. A workflow for quantification of lymphatic vessel parameters in 3-D volume images. Cleared liver tissue was stained with LYVE1 (red) for lym- phatic vessels (LVs) and reconstructed three-dimensional (3-D) images of the portal tract in the mouse liver (EC-GFP reporter mouse) were created. The “Surface” rendering tool in Imaris software were used to determine a total volume of LYVE1-positive LVs (A–C), whereas the “Filament Tracer” rendering tool was used for quantification of the diameter and branch number of LVs (D–F). A:LYVE1-positive LVs were captured based on fluorescence intensities. B: thresholds were manually adjusted to determine LVs. C:Rendered LYVE1-positive LVs were visually checked to confirm proper vascular connections. LVs with improper connections and/or speckled background structure were removed manually. D: LYVE1-positive LVs were captured based on fluores- cence intensities using automatic filament and path detection in the “Filament Tracer” rendering tool. E: thresholds were manually adjusted to determine LVs. F: LVs with disconnected and speckled background structures were removed manually. All outputs of LV parameters were exported to Excel files for statistical analysis. EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.

Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17), sheep anti-rat LYVE1 (1:100, AF7939, R&D Systems) (18), and rabbit anti-COL-I (1:100, ab292, Abcam) (19) primary antibodies at 4 C overnight, followed by washing with PBS for 5 min for 3 times and incubation with secondary antibodies including donkey anti-goat Alexa 647 (1:300, A32849, Invitrogen), donkey anti-sheep Alexa 647 (1:300, A21448, Invitrogen), and donkey anti-rabbit Alexa 488 at room temperature for 30 min. For immunostaining of PDPN in human liver slides, we amplified fluorescence signal using the avidin-biotin amplification method (SP-2001, Vector Laboratories, Newark, CA).

Techniques: Staining, Software

Figure 6. Comparison of lymphatic vessel parameters between 3-D volume-rendering images and conventional two-dimensional (2-D) images in normal and biliary fibrotic livers. A, left: reconstructed three-dimensional (3-D) image of the portal tract in the liver from a sham-operated mouse (EC-GFP re- porter mouse). Imaging condition: z-step size ¼ 0.4 μm step, image volume [x] [y] [z] ¼ 777 μm 777 μm 215 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel: LV) and aSMA (white, portal vein: PV). Right: 3-D volume-rendering image of lymphatic vessels and portal vein using Imaris software. Scale bars: 100 μm. B, left: reconstructed 3-D image of the portal tract in the liver from a 4-wk BDL mouse (EC-GFP reporter mouse). Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 793 μm 894 μm 190 μm. Right: 3-D volume-rendering image of lym- phatic vessels and portal vein using Imaris software. Scale bars: 100 μm. C: quantification of lymphatic vessel (LV) parameters (diameter, branch number, and total volume) from 3-D volume-rendering images in sham (n ¼ 4) and 4-wk BDL (n ¼ 3) mouse livers. PT, portal tract; FC, fold change. D: conventional 2-D images of liver tissues (frozen section, 7-lm thickness) from sham and 4-wk BDL mice (EC-GFP reporter mice). Red: LYVE1-positive lymphatic vessel. Scale bars: 100 μm. E: quantification of LV parameters (diameter, number, and total area) from conventional 2-D images in sham (n ¼ 6) and 4-wk BDL (n ¼ 6) mouse livers. BDL, bile duct ligation; EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Article Title: An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.

doi: 10.1152/ajpgi.00139.2023

Figure Lengend Snippet: Figure 6. Comparison of lymphatic vessel parameters between 3-D volume-rendering images and conventional two-dimensional (2-D) images in normal and biliary fibrotic livers. A, left: reconstructed three-dimensional (3-D) image of the portal tract in the liver from a sham-operated mouse (EC-GFP re- porter mouse). Imaging condition: z-step size ¼ 0.4 μm step, image volume [x] [y] [z] ¼ 777 μm 777 μm 215 μm. Liver tissue was cleared and stained with LYVE1 (red, lymphatic vessel: LV) and aSMA (white, portal vein: PV). Right: 3-D volume-rendering image of lymphatic vessels and portal vein using Imaris software. Scale bars: 100 μm. B, left: reconstructed 3-D image of the portal tract in the liver from a 4-wk BDL mouse (EC-GFP reporter mouse). Imaging condition: z-step size ¼ 0.4 μm, image volume [x] [y] [z] ¼ 793 μm 894 μm 190 μm. Right: 3-D volume-rendering image of lym- phatic vessels and portal vein using Imaris software. Scale bars: 100 μm. C: quantification of lymphatic vessel (LV) parameters (diameter, branch number, and total volume) from 3-D volume-rendering images in sham (n ¼ 4) and 4-wk BDL (n ¼ 3) mouse livers. PT, portal tract; FC, fold change. D: conventional 2-D images of liver tissues (frozen section, 7-lm thickness) from sham and 4-wk BDL mice (EC-GFP reporter mice). Red: LYVE1-positive lymphatic vessel. Scale bars: 100 μm. E: quantification of LV parameters (diameter, number, and total area) from conventional 2-D images in sham (n ¼ 6) and 4-wk BDL (n ¼ 6) mouse livers. BDL, bile duct ligation; EC-GFP, Endothelial-specific green fluorescent protein mice; LV, lymphatic vessel.

Article Snippet: The liver slides were washed with PBS and incubated in blocking buffer (PBS containing 5% donkey serum and 0.3% triton X-100) at room temperature for 1 h. After blocking was completed, the liver slides were incubated with goat anti-mouse LYVE1 (1:200, AF2125, R&D Systems, Minneapolis, MN) (17), sheep anti-rat LYVE1 (1:100, AF7939, R&D Systems) (18), and rabbit anti-COL-I (1:100, ab292, Abcam) (19) primary antibodies at 4 C overnight, followed by washing with PBS for 5 min for 3 times and incubation with secondary antibodies including donkey anti-goat Alexa 647 (1:300, A32849, Invitrogen), donkey anti-sheep Alexa 647 (1:300, A21448, Invitrogen), and donkey anti-rabbit Alexa 488 at room temperature for 30 min. For immunostaining of PDPN in human liver slides, we amplified fluorescence signal using the avidin-biotin amplification method (SP-2001, Vector Laboratories, Newark, CA).

Techniques: Comparison, Imaging, Staining, Software, Ligation

β-Catenin is necessary for the development of LVVs, LVs, VVs, and cardiac valves. ( A – J ) The gene encoding β-catenin ( Ctnnb1 ) was deleted from LECs, LVV-ECs, LV-ECs, and VV-ECs using Lyve1-Cre mice . IHC was performed for the indicated markers. Frontal sections from E14.5 ( A – D ) and E16.5 ( G , H ) embryos revealed the LVVs in controls (arrows) but not in their Lyve1-Cre; Ctnnb1 LOF littermates. Arrowheads point to the valve-forming area of mutants. ( G , H ) At E16.5, VVs are seen in control embryos (yellow arrows) but not in mutants. ( E , F ) SEM confirmed the presence of LVV-ECs (magenta) and VV-ECs (green) in E14.5 control embryos and their absence in Lyve1-Cre;Ctnnb1 LOF littermates. ( I , J ) Whole-mount IHC of the mesenteric lymphatic vessels revealed the presence of LVs in E18.5 control (arrows) but not Lyve1-Cre;Ctnnb1 LOF littermates. ( I ) Furthermore, PROX1 is strongly expressed in the LVs but down-regulated elsewhere in the lymphatic vessels of controls. ( J ) In contrast, PROX1 expression is uniformly high in the lymphatic vessels of the mutants. ( K , L ) Prox1 +/ Cre was used to delete Ctnnb1 from the PROX1 + cells of the cardiac semilunar valves. IHC was performed for the indicated markers. E13.5 Prox1 +/ Cre ; Ctnnb1 LOF embryos lacked the PROX1 + FOXC2 + cells of the cardiac valves (arrows). (LS) Lymph sacs; (IJV) internal jugular vein; (SCV) subclavian vein; (SVC) superior vena cava. Bars: A – J , 200 µm; K , L , 100 µm. n = 4 for each experiment.

Journal: Genes & Development

Article Title: Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves

doi: 10.1101/gad.282400.116

Figure Lengend Snippet: β-Catenin is necessary for the development of LVVs, LVs, VVs, and cardiac valves. ( A – J ) The gene encoding β-catenin ( Ctnnb1 ) was deleted from LECs, LVV-ECs, LV-ECs, and VV-ECs using Lyve1-Cre mice . IHC was performed for the indicated markers. Frontal sections from E14.5 ( A – D ) and E16.5 ( G , H ) embryos revealed the LVVs in controls (arrows) but not in their Lyve1-Cre; Ctnnb1 LOF littermates. Arrowheads point to the valve-forming area of mutants. ( G , H ) At E16.5, VVs are seen in control embryos (yellow arrows) but not in mutants. ( E , F ) SEM confirmed the presence of LVV-ECs (magenta) and VV-ECs (green) in E14.5 control embryos and their absence in Lyve1-Cre;Ctnnb1 LOF littermates. ( I , J ) Whole-mount IHC of the mesenteric lymphatic vessels revealed the presence of LVs in E18.5 control (arrows) but not Lyve1-Cre;Ctnnb1 LOF littermates. ( I ) Furthermore, PROX1 is strongly expressed in the LVs but down-regulated elsewhere in the lymphatic vessels of controls. ( J ) In contrast, PROX1 expression is uniformly high in the lymphatic vessels of the mutants. ( K , L ) Prox1 +/ Cre was used to delete Ctnnb1 from the PROX1 + cells of the cardiac semilunar valves. IHC was performed for the indicated markers. E13.5 Prox1 +/ Cre ; Ctnnb1 LOF embryos lacked the PROX1 + FOXC2 + cells of the cardiac valves (arrows). (LS) Lymph sacs; (IJV) internal jugular vein; (SCV) subclavian vein; (SVC) superior vena cava. Bars: A – J , 200 µm; K , L , 100 µm. n = 4 for each experiment.

Article Snippet: Primary antibodies used for immunostaining were as follows: rabbit anti-PROX1 (AngioBio), goat anti-human PROX1 (R&D Systems), sheep anti-mouse FOXC2 (R&D Systems), goat anti-mouse VEGFR3 (R&D Systems), goat anti-mouse LYVE1 (R&D Systems), rat anti-mouse CD31 (BD Pharmingen), goat anti-mouse GATA2 (R&D Systems), rabbit anti-total β-catenin and rabbit anti-active β-catenin antibodies (both from Cell Signaling Technologies), goat anti-mouse NRP2 (R&D Systems), chicken anti-GFP (Abcam), rat anti-mouse Endomucin (eBioscience), rabbit anti-CX37 (Invitrogen), and Cy3-conjugated monoclonal anti-α-SMA (Sigma-Aldrich).

Techniques: Control, Expressing

β-Catenin is necessary for the patterning of lymphatic vessels. ( A – G ) E17.5 and E14.5 Lyve1-Cre;Ctnnb1 LOF and its control littermates were harvested, and the lymphatic vessels of dorsal skin were analyzed by whole-mount IHC for the indicated markers. ( A , B ) The lymphatic vessels of control embryos have reached and crossed over the midline (red dotted line) to form a network of vessels. In contrast, the lymphatic vessels of the mutants are dilated and have not reached the midline. Additionally, abnormal recruitment of α-SMA + mural cells is visible in the lymphatic vessels of mutants. The lymphatic vessel diameter is quantified in C . ( D , E ) The lymphatic vessels at the leading edge are thin and elongated in E14.5 control embryos. In contrast, they are dilated in Lyve1-Cre;Ctnnb1 LOF embryos. D ′ and E ′ show NRP2 expression alone from the corresponding pictures in D and E , respectively. NRP2 clearly labels the filopodia (red asterisks) on the tip cells of the growing lymphatic vessels. The length ( F ) and the number ( G ) of filapodia are significantly reduced in the mutant embryos. Bars: A , B , 500 µm; D – E ′, 50 µm. n = 4 for each experiment. (**) P < 0.01.

Journal: Genes & Development

Article Title: Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves

doi: 10.1101/gad.282400.116

Figure Lengend Snippet: β-Catenin is necessary for the patterning of lymphatic vessels. ( A – G ) E17.5 and E14.5 Lyve1-Cre;Ctnnb1 LOF and its control littermates were harvested, and the lymphatic vessels of dorsal skin were analyzed by whole-mount IHC for the indicated markers. ( A , B ) The lymphatic vessels of control embryos have reached and crossed over the midline (red dotted line) to form a network of vessels. In contrast, the lymphatic vessels of the mutants are dilated and have not reached the midline. Additionally, abnormal recruitment of α-SMA + mural cells is visible in the lymphatic vessels of mutants. The lymphatic vessel diameter is quantified in C . ( D , E ) The lymphatic vessels at the leading edge are thin and elongated in E14.5 control embryos. In contrast, they are dilated in Lyve1-Cre;Ctnnb1 LOF embryos. D ′ and E ′ show NRP2 expression alone from the corresponding pictures in D and E , respectively. NRP2 clearly labels the filopodia (red asterisks) on the tip cells of the growing lymphatic vessels. The length ( F ) and the number ( G ) of filapodia are significantly reduced in the mutant embryos. Bars: A , B , 500 µm; D – E ′, 50 µm. n = 4 for each experiment. (**) P < 0.01.

Article Snippet: Primary antibodies used for immunostaining were as follows: rabbit anti-PROX1 (AngioBio), goat anti-human PROX1 (R&D Systems), sheep anti-mouse FOXC2 (R&D Systems), goat anti-mouse VEGFR3 (R&D Systems), goat anti-mouse LYVE1 (R&D Systems), rat anti-mouse CD31 (BD Pharmingen), goat anti-mouse GATA2 (R&D Systems), rabbit anti-total β-catenin and rabbit anti-active β-catenin antibodies (both from Cell Signaling Technologies), goat anti-mouse NRP2 (R&D Systems), chicken anti-GFP (Abcam), rat anti-mouse Endomucin (eBioscience), rabbit anti-CX37 (Invitrogen), and Cy3-conjugated monoclonal anti-α-SMA (Sigma-Aldrich).

Techniques: Control, Expressing, Mutagenesis

The Wnt/β-catenin signaling pathway regulates FOXC2 expression in LECs. ( A – D ) The dorsal skin of E15.5 control ( A , B ) and Lyve1-Cre;Ctnnb1 LOF ( C , D ) embryos was analyzed by whole-mount IHC for the indicated markers. FOXC2 is expressed in both the tip ( A , A ′, arrows) and collecting lymphatic vessels ( B , B ′, arrows) of control embryos. ( B , B ′) Rudimentary LVs are enriched for FOXC2 (arrowhead). ( C , C ′) FOXC2 expression is dramatically down-regulated in the tip cells (arrows) of mutants. ( D , D ′) A modest down-regulation of FOXC2 expression is observed in the collecting lymphatic vessels of mice lacking β-catenin (arrows). Furthermore, LV rudiments are absent in Lyve1-Cre;Ctnnb1 LOF embryos. ( E – G ) The lymphatic vessels of the skin from E16.5 control and Foxc2 −/− littermates were analyzed by IHC using the indicated markers. The magenta lines indicate the distance between the tip cells and the opposing front. ( G ) This distance is significantly increased in Foxc2 −/− embryos, indicating lymphatic vascular hypoplasia. The diameter of lymphatic vessels is also significantly increased in Foxc2 −/− embryos. ( H – J ) The tip cells of E15.5 control embryos have numerous well-formed filopodia (red dots). In contrast, the tip cells of Foxc2 −/− embryos have a bulbous architecture and hardly any filopodia. The number and length of filopodia in control and Foxc2 −/− embryos are quantified in J . Bars: A – D , 100 µm; E , F , 500 µm; H , I , 25 µm. n = 4 for each experiment. (**) P < 0.01; (***) P < 0.001.

Journal: Genes & Development

Article Title: Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves

doi: 10.1101/gad.282400.116

Figure Lengend Snippet: The Wnt/β-catenin signaling pathway regulates FOXC2 expression in LECs. ( A – D ) The dorsal skin of E15.5 control ( A , B ) and Lyve1-Cre;Ctnnb1 LOF ( C , D ) embryos was analyzed by whole-mount IHC for the indicated markers. FOXC2 is expressed in both the tip ( A , A ′, arrows) and collecting lymphatic vessels ( B , B ′, arrows) of control embryos. ( B , B ′) Rudimentary LVs are enriched for FOXC2 (arrowhead). ( C , C ′) FOXC2 expression is dramatically down-regulated in the tip cells (arrows) of mutants. ( D , D ′) A modest down-regulation of FOXC2 expression is observed in the collecting lymphatic vessels of mice lacking β-catenin (arrows). Furthermore, LV rudiments are absent in Lyve1-Cre;Ctnnb1 LOF embryos. ( E – G ) The lymphatic vessels of the skin from E16.5 control and Foxc2 −/− littermates were analyzed by IHC using the indicated markers. The magenta lines indicate the distance between the tip cells and the opposing front. ( G ) This distance is significantly increased in Foxc2 −/− embryos, indicating lymphatic vascular hypoplasia. The diameter of lymphatic vessels is also significantly increased in Foxc2 −/− embryos. ( H – J ) The tip cells of E15.5 control embryos have numerous well-formed filopodia (red dots). In contrast, the tip cells of Foxc2 −/− embryos have a bulbous architecture and hardly any filopodia. The number and length of filopodia in control and Foxc2 −/− embryos are quantified in J . Bars: A – D , 100 µm; E , F , 500 µm; H , I , 25 µm. n = 4 for each experiment. (**) P < 0.01; (***) P < 0.001.

Article Snippet: Primary antibodies used for immunostaining were as follows: rabbit anti-PROX1 (AngioBio), goat anti-human PROX1 (R&D Systems), sheep anti-mouse FOXC2 (R&D Systems), goat anti-mouse VEGFR3 (R&D Systems), goat anti-mouse LYVE1 (R&D Systems), rat anti-mouse CD31 (BD Pharmingen), goat anti-mouse GATA2 (R&D Systems), rabbit anti-total β-catenin and rabbit anti-active β-catenin antibodies (both from Cell Signaling Technologies), goat anti-mouse NRP2 (R&D Systems), chicken anti-GFP (Abcam), rat anti-mouse Endomucin (eBioscience), rabbit anti-CX37 (Invitrogen), and Cy3-conjugated monoclonal anti-α-SMA (Sigma-Aldrich).

Techniques: Expressing, Control

FOXC2 compensates for the loss of β-catenin to regulate lymphatic vessel patterning. ( A – E ) Primary human LECs were infected with control or FOXC2-expressing retroviral particles. Scratch assay was performed 24 h later in the presence or absence of 25 µM iCRT3. The space between the red dotted lines indicates the open scratch wound. ( E ) The wound size was measured at various time points and plotted. iCRT3 significantly inhibits the ability of control LECs to “heal” the scratch wound. FOXC2-overexpressing cells are able to significantly overcome iCRT3-induced inhibition. ( F – I ) The lymphatic vessels of the dorsal skin of E16.5 control ( F ), Lyve1-Cre;Ctnnb1 LOF ( G ), Lyve1-Cre;Ctnnb1 LOF ;FOXC2 GOF ( H ), and Lyve1-Cre ;FOXC2 GOF ( I ) embryos were analyzed by IHC for VEGFR3. ( J ) The diameter of the vessels and the distance between the tip cells of the opposing fronts were quantified ( Supplemental Fig. 7E–H ) and plotted. In comparison with control embryos, the lymphatic vessels of Lyve1-Cre;Cttnb1 LOF embryos are significantly dilated. The distance between the migrating fronts is also significantly increased, indicating lymphatic vascular hypoplasia. Ectopic expression of FOXC2 significantly rescues these defects. ( K – N ) Coimmunohistochemistry for the indicated markers revealed the presence of α-SMA + mural cells on the VEGFR3 + lymphatic vessels of Lyve1-Cre;Cttnb1 LOF embryos (shown in L ). ( M ) This defect is fully rescued by ectopic expression of FOXC2. Lower magnification pictures of F – I and K – N are presented in Supplemental Figure 7 . ( O – R ) The mesenteric lymphatic vessels of E17.5 embryos were analyzed by IHC for the indicated markers. Dilation of lymphatic vessels and the abnormal recruitment of α-SMA + mural cells caused by the loss of β-catenin were rescued by FOXC2 overexpression. LVs are seen in control (arrow) but not in any of the mutant embryos. ( S ) Model for the relationship between OSS, β-catenin, FOXC2, and PROX1 during lymphatic vascular development. We did not exclude the role of yet to be identified Wnt ligands that function independently or in cooperation with OSS to activate β-catenin. Bars, 100 µm. ( A – E ) n = 3. ( F – R ) n = 4. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.

Journal: Genes & Development

Article Title: Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves

doi: 10.1101/gad.282400.116

Figure Lengend Snippet: FOXC2 compensates for the loss of β-catenin to regulate lymphatic vessel patterning. ( A – E ) Primary human LECs were infected with control or FOXC2-expressing retroviral particles. Scratch assay was performed 24 h later in the presence or absence of 25 µM iCRT3. The space between the red dotted lines indicates the open scratch wound. ( E ) The wound size was measured at various time points and plotted. iCRT3 significantly inhibits the ability of control LECs to “heal” the scratch wound. FOXC2-overexpressing cells are able to significantly overcome iCRT3-induced inhibition. ( F – I ) The lymphatic vessels of the dorsal skin of E16.5 control ( F ), Lyve1-Cre;Ctnnb1 LOF ( G ), Lyve1-Cre;Ctnnb1 LOF ;FOXC2 GOF ( H ), and Lyve1-Cre ;FOXC2 GOF ( I ) embryos were analyzed by IHC for VEGFR3. ( J ) The diameter of the vessels and the distance between the tip cells of the opposing fronts were quantified ( Supplemental Fig. 7E–H ) and plotted. In comparison with control embryos, the lymphatic vessels of Lyve1-Cre;Cttnb1 LOF embryos are significantly dilated. The distance between the migrating fronts is also significantly increased, indicating lymphatic vascular hypoplasia. Ectopic expression of FOXC2 significantly rescues these defects. ( K – N ) Coimmunohistochemistry for the indicated markers revealed the presence of α-SMA + mural cells on the VEGFR3 + lymphatic vessels of Lyve1-Cre;Cttnb1 LOF embryos (shown in L ). ( M ) This defect is fully rescued by ectopic expression of FOXC2. Lower magnification pictures of F – I and K – N are presented in Supplemental Figure 7 . ( O – R ) The mesenteric lymphatic vessels of E17.5 embryos were analyzed by IHC for the indicated markers. Dilation of lymphatic vessels and the abnormal recruitment of α-SMA + mural cells caused by the loss of β-catenin were rescued by FOXC2 overexpression. LVs are seen in control (arrow) but not in any of the mutant embryos. ( S ) Model for the relationship between OSS, β-catenin, FOXC2, and PROX1 during lymphatic vascular development. We did not exclude the role of yet to be identified Wnt ligands that function independently or in cooperation with OSS to activate β-catenin. Bars, 100 µm. ( A – E ) n = 3. ( F – R ) n = 4. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.

Article Snippet: Primary antibodies used for immunostaining were as follows: rabbit anti-PROX1 (AngioBio), goat anti-human PROX1 (R&D Systems), sheep anti-mouse FOXC2 (R&D Systems), goat anti-mouse VEGFR3 (R&D Systems), goat anti-mouse LYVE1 (R&D Systems), rat anti-mouse CD31 (BD Pharmingen), goat anti-mouse GATA2 (R&D Systems), rabbit anti-total β-catenin and rabbit anti-active β-catenin antibodies (both from Cell Signaling Technologies), goat anti-mouse NRP2 (R&D Systems), chicken anti-GFP (Abcam), rat anti-mouse Endomucin (eBioscience), rabbit anti-CX37 (Invitrogen), and Cy3-conjugated monoclonal anti-α-SMA (Sigma-Aldrich).

Techniques: Infection, Control, Expressing, Retroviral, Wound Healing Assay, Inhibition, Comparison, Over Expression, Mutagenesis

( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and LYVE1 (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.

Journal: eLife

Article Title: EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity

doi: 10.7554/eLife.57732

Figure Lengend Snippet: ( A ) Experimental scheme for Ephb4 deletion in the mature vasculature by three consecutive intraperitoneal (i.p.) 4-OHT injections (arrowheads) into 3-week-old Ephb4 flox ;R26-mTmG;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence from 7-week-old Ephb4 mice using antibodies against VE-cadherin (green) and LYVE1 (red) or GFP (single channel images). GFP expression demonstrates Cre recombination in arteries (A), veins (V) and LYVE1 - collecting lymphatic vessels (Lcol), but not LYVE1 + lymphatic capillaries (Lcap) in control ear. Mutant collecting vessels show abnormal LYVE1 expression. ( B ) Ear skin whole-mount immunofluorescence of 7-week-old Ephb4 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Ephb4 mutant compared to heterozygous littermates. ( C ) Experimental scheme for Efnb2 deletion in the mature vasculature by 3 consecutive 4-OHT injections (arrowheads) into 3-week-old Efnb2 flox ;Pdgfb-CreER T2 mice. Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using antibodies against VE-cadherin (green) and LYVE1 (red). ( D ) Ear skin whole-mount immunofluorescence of 5-week-old Efnb2 mice using an antibody against VE-cadherin. Note altered morphology of collecting lymphatic vessel junctions (arrow) in Efnb2 mutant compared to Cre negative littermates already after 2 weeks of Cre induction. ( E ) In vivo basal permeability assay in skin and lung of 5-week-old Efnb2 mutants and Cre negative littermates. Data represent mean ± s.e.m. (n = 6–7 mice from two independent experiments). Efnb2 deletion does not impact on basal barrier function of skin and lung blood vasculature. ( F ) Experimental scheme for Efnb2 deletion using the Cdh5-CreER T2 line and three consecutive tamoxifen injections (arrowheads). Vascular leakage in the skin of 5-week-old Efnb2 mutants and Cre negative littermates was induced with VEGF or histamine. Note, endothelial deletion of Efnb2 does not impact on junctional regulation in leakage-induced dermal blood vasculature. Data represent mean ± s.e.m. (n = 7-8 mice from two independent experiments). Western blot from total lung lysates 8 days after the first tamoxifen administration showing depletion of EphrinB2 in Cre + mice. VE-cadherin was used as a loading control. Source data for panels ( E,F ) are provided. Scale bars: 100 μm ( A,C ), 10 μm ( B,D ). Figure 1—source data 1. Flow cytometric analysis of endothelial cell proliferation in postnatal mouse ear skin.

Article Snippet: Antibody , anti-mouse LYVE1 (Rat monoclonal) , R and D Systems , Cat# MAB2125 , (1 μg/ml).

Techniques: Immunofluorescence, Expressing, Control, Mutagenesis, In Vivo, Permeability, Western Blot

Journal: eLife

Article Title: EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity

doi: 10.7554/eLife.57732

Figure Lengend Snippet:

Article Snippet: Antibody , anti-mouse LYVE1 (Rat monoclonal) , R and D Systems , Cat# MAB2125 , (1 μg/ml).

Techniques: Mutagenesis, Isolation, Sequencing, Negative Control, Recombinant, Activation Assay